ResearchMoz

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

GBI Research
Published Date » 2014-06-02
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The...
Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Introduction 9
2.1 Breast Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.6.1 Classification 13
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 14
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Herceptin 20
3.1.2 Halaven 21
3.1.3 Avastin 22
3.1.4 Gemzar 23
3.1.5 Taxotere 23
3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 26
3.1.9 Zoladex 26
3.1.10 Arimidex 27
3.2 Heat Map for Marketed Products 27

4 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Pipeline Analysis 29
4.1 Overall Pipeline 29
4.2 Pipeline Analysis by Molecule Type 31
4.3 Pipeline Analysis by Mechanism of Action 33
4.4 Clinical Trials - Failure Rate 35
4.5 Clinical Trial Size 37
4.6 Duration 39
4.7 Promising Drug Candidates in Pipeline 40
4.7.1 Buparlisib 40
4.7.2 Palbociclib 40
4.7.3 Afatinib dimaleate 40
4.7.4 Entinostat 41
4.7.5 Neratinib 42
4.7.6 BMN-673 42
4.7.7 Etirinotecan pegol 42
4.7.8 MetmAb (onartuzumab) 43

5 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Market Forecast to 2020 44
5.1 Global Market 44
5.1.1 Treatment Use Patterns 44
5.1.2 Market Size 44
5.2 North America 46
5.2.1 Treatment Use Patterns 46
5.2.2 Annual Cost of Therapy 47
5.2.3 Market Size 49
5.3 Top Five European Markets 51
5.3.1 Treatment Use Patterns 51
5.3.2 Annual Cost of Therapy 52
5.3.3 Market Size 53
5.4 Japan 54
5.4.1 Treatment Use Patterns 54
5.4.2 Annual Cost of Therapy 54
5.4.3 Market Size 54
5.5 Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020 56
5.5.1 Drivers 56
5.5.2 Barriers 56

6 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Deals and Strategic Consolidations 58
6.1 Licensing Agreements 58
6.1.1 Major Licensing Deals 61
6.2 Co-development Agreements 62
6.2.1 Major Co-development Agreements 64

7 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Appendix 66
7.1 All Pipeline Drugs by Phase 66
7.1.1 Discovery 66
7.1.2 Preclinical 69
7.1.3 IND/CTA-Filed and Phase I 79
7.1.4 Phase II 85
7.1.5 Phase III 91
7.1.6 Pre-Registration 93
7.2 Market Forecasts to 2020 94
7.2.1 Global 94
7.2.2 US 94
7.2.3 Canada 95
7.2.4 UK 95
7.2.5 France 95
7.2.6 Germany 96
7.2.7 Italy 96
7.2.8 Spain 96
7.2.9 Japan 97
7.3 Market Definitions 97
7.4 Abbreviations 97
7.5 References 99
7.6 Research Methodology 102
7.6.1 Coverage 102
7.6.2 Secondary Research 102
7.6.3 Primary Research 103
7.6.4 Therapeutic Landscape 103
7.6.5 Geographical Landscape 105
7.6.6 Pipeline Analysis 106
7.7 Expert Panel Validation 106
7.8 Contact Us 106
7.9 Disclaimer 106

List of Tables

Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 12
Table 2: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 13
Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 66
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 69
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 79
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 85
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 91
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 93
Table 9: Breast Cancer Therapeutics, Global, Forecast Data, 2013–2020 94
Table 10: Breast Cancer Therapeutics, US, Forecast Data, 2013–2020 94
Table 11: Breast Cancer Therapeutics, Canada, Forecast Data, 2013–2020 95
Table 12: Breast Cancer Therapeutics, UK, Forecast Data, 2013–2020 95
Table 13: Breast Cancer Therapeutics, France, Forecast Data, 2013–2020 95
Table 14: Breast Cancer Therapeutics, Germany, Forecast Data, 2013–2020 96
Table 15: Breast Cancer Therapeutics, Italy, Forecast Data, 2013–2020 96
Table 16: Breast Cancer Therapeutics, Spain, Forecast Data, 2013–2020 96
Table 17: Breast Cancer Therapeutics, Japan, Forecast Data, 2013–2020 97

List of Figures

Figure 1: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 17
Figure 2: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 18
Figure 3: Breast Cancer Therapeutics, Global, Heat Map (Marketed Products) 28
Figure 4: Breast Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013 30
Figure 5: Breast Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013 32
Figure 6: Breast Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34
Figure 7: Breast Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Figure 8: Breast Cancer Therapeutics, Global, Clinical Trial Size, 2013 38
Figure 9: Breast Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013 39
Figure 10: Breast Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size ($bn), 2013–2020 45
Figure 11: Breast Cancer Therapeutics, US and Canada, Treatment Use Patterns (‘000), 2013–2020 46
Figure 12: Breast Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013–2020 48
Figure 13: Breast Cancer Therapeutics, US and Canada, Market Size ($m), 2013–2020 50
Figure 14: Breast Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns (‘000), 2013–2020 51
Figure 15: Breast Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013–2020 52
Figure 16: Breast Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013–2020 53
Figure 17: Breast Cancer Therapeutics, Japan, Treatment Use Pattern, Annual Cost of Therapy and Market Size, 2013–2020 55
Figure 18: Breast Cancer Therapeutics, Global, Licensing Deals by Phase and Value, 2006–2013 58
Figure 19: Breast Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2013 59
Figure 20: Breast Cancer Therapeutics, Global, Licensing Deals by Region, 2006–2013 60
Figure 21: Breast Cancer Therapeutics, Global, Co-development Deals by Phase and Value, 2006–2013 62
Figure 22: Breast Cancer Therapeutics, Global, Co-development Deals, 2006–2013 63
Figure 23: GBI Research Market Forecasting Model 105

Upcoming Reports:

Poland: concrete products market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the concrete products market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the concrete products market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Asphalt Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Asphalt is the refined residue from the distillation process of specific crude oils. It is primarily used in road construction as a glue or binder and is mixed with aggregate particles for creating asphalt concrete. The other main applications of asphalt include production of roofing felt, bituminous waterproofing products and sealing flat roofs among others. The global demand for asphalt is increasing owing to the growth in the construction industry especially in the emerging economies such as China, India and Brazil. The application that are driving the demand for asphalt...
Contactless Payments Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Efficiency, reliability and speed are the major cornerstone for modern economy. Cash dominated the world’s payment history for centuries. Today, as consumers want payment through mobile phones and online, there is increase in shift towards the cashless society. Contactless payment allows payment of transactions without any physical connection between point of sales terminal and consumer payment device. Additionally, contactless payments are perceived to be significantly faster than cash transactions or Chip & PIN transactions thereby reducing the queuing time. The...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...
Anti-UAW Workers to Form Another Union at Volkswagen Plant
Aug 27, 2014  
Employees at the Chattanooga plant of Volkswagen AG are trying to form a union of company’s salaried and hourly workers, as a means to counter the United Auto Workers Local 42 union that was established last month.  The new union is expected to force Volkswagen in rethinking and holding another vote to determine which union is favored by hourly employees. UAV had earlier...
Fairchild Axing 15% of its Workforce with Multiple Plant Closures
Aug 27, 2014  
American semiconductor manufacturer Fairchild has said that it will be laying off nearly 15% of its global workforce following the closure of its facilities in Malaysia, Utah, and Korea. The company will cease the production of five-inch silicon from its plant in Bucheon, Korea. It will also scale down its capacity to produce six-inch wafers. The company will bring these closures into effect...